Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has

monoclonal antibodies
daunorubicin
hysterectomy
leukemia
refractory acute myeloid leukemia (aml)
  • 14 views
  • 16 Jun, 2022
  • 1 location
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

This study is an open-label, single arm phase II study which will examine the efficacy and toxicity of the combination therapy of GO, mitoxantrone and etoposide in patients who did not respond to first line induction therapy.

cytarabine
gemtuzumab
mitoxantrone
blast cells
neoadjuvant therapy
  • 0 views
  • 25 Mar, 2022
  • 1 location
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

chemotherapy, such as cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin, in participants with blood cancers.

cancer chemotherapy
growth factor
idarubicin
hematologic malignancy
hematopoietic growth factors
  • 26 views
  • 23 Mar, 2022
  • 1 location
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

This is a Phase Ib Study to determine the Maximum Tolerated Dose (MTD) of Venetoclax in combination with Gemtuzumab Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia

gemtuzumab
azacitidine
tretinoin
blast cells
refractory acute myeloid leukemia (aml)
  • 16 views
  • 22 Mar, 2022
  • 4 locations
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

This phase I study hopes to explore how safe and tolerable is the combination of gemtuzumab ozogamicin (GO) and midostaurin, with the standard induction therapy (cytarabine and daunorubicin) in

gemtuzumab
daunorubicin
neoadjuvant therapy
cytarabine
tyrosine
  • 2 views
  • 05 Jun, 2022
  • 1 location
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" [cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)] in

graft versus host disease
refractory acute myeloid leukemia (aml)
hydroxyurea
cytarabine
cancer
  • 8 views
  • 15 Mar, 2022
  • 1 location
CPX-351+GO in Subjects 55 Years Old, or Older, With AML

This is an open label study to assess the safety and efficacy of CPX-351 in combination with gemtuzumab ozogamicin (GO) as first intensive therapy in older (age >55 years) subjects with newly

remission
gemtuzumab
daunorubicin
blast cells
anthracyclines
  • 0 views
  • 29 Dec, 2021
  • 1 location
Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD. Role of a post-SCT maintenance with glasdegib.

myelodysplastic syndromes
gemtuzumab
daunorubicin
blast cells
ejection fraction
  • 0 views
  • 22 Mar, 2022
  • 18 locations
Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities

and septic shock. Today, data about sepsis/septic shock are scarce. The objective was to investigate reports of sepsis/septic shock adverse events related to ADC, including Gemtuzumab

septic shock
cancer
shock
  • 0 views
  • 10 May, 2022
  • 1 location
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

There is currently lack of collaborative data on the epidemiology, clinicopathologic features and treatment outcome of newly diagnosed and relapsed APL in Asia. In addition, there is lack of data comparing oral- As2O3-based regimens with other treatment approaches, including intravenous As2O3,in the frontline or relapsed setting. With the long-term data …

  • 0 views
  • 25 Feb, 2022